Informations:
Erreur:
ID
21436
Description
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00574236
Lien
https://clinicaltrials.gov/show/NCT00574236
Mots-clés
Versions (1)
- 21/04/2017 21/04/2017 -
Téléchargé le
21 avril 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Metastatic Breast Cancer NCT00574236
Eligibility Metastatic Breast Cancer NCT00574236
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT00574236
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Metastatic breast cancer
Item
cytologically or histologically confirmed metastatic breast cancer
boolean
C0278488 (UMLS CUI [1])
Measurable or evaluable disease
Item
measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
C1516986 (UMLS CUI [2])
Age
Item
age > 18, ps 0,1,2
boolean
C0001779 (UMLS CUI [1])
Ejection fraction percent muga
Item
muga > 45%
boolean
C0743402 (UMLS CUI [1])
Prior therapy
Item
received one or fewer chemotherapies or investigational regimens for metastatic disease, no limit to the number of prior hormonal therapies. may have had single agent herceptin and/or herceptin plus single-agent chemotx.
boolean
C1514463 (UMLS CUI [1])
Laboratory test result
Item
must meet designated laboratory criteria within 14 days of enrollment
boolean
C2346633 (UMLS CUI [1])
Doxorubicin
Item
doxorubicin for metatstatic disease.
boolean
C0013089 (UMLS CUI [1])
Gynaecological status
Item
pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Active infection, myocardial infarction
Item
active infections, no myocardial infarction within 2 months of enrollment.
boolean
C0009450 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C0027051 (UMLS CUI [2])
Experimental drugs
Item
investigational drugs within 14 days of enrollment.
boolean
C0304229 (UMLS CUI [1])
Chemotherapy, radiotherapy, hormonal therapy or other investigational therapy
Item
chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within 4 weeks of enrollment.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0949266 (UMLS CUI [4])
C1522449 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0949266 (UMLS CUI [4])
Neuropathy grade
Item
neuropathy that is > grade 2.
boolean
C0442874 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
C0441800 (UMLS CUI [1,2])
Brain metastases
Item
active brain mets.
boolean
C0220650 (UMLS CUI [1])
Hypersensitivity to bortezomib, boron, or mannitol
Item
hypersensitivity to bortezomib, boron, or mannitol
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0006030 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0024730 (UMLS CUI [3,2])
C1176309 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0006030 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0024730 (UMLS CUI [3,2])